DexCom Announces Joint Development Agreement with Animas Corporation

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), a leading provider of continuous glucose monitoring systems for people with diabetes, today announced that it has entered into a joint development agreement with Animas Corporation to integrate DexCom’s continuous glucose monitoring (CGM) technology into Animas® insulin pumps. The new product will be based on Animas’ advanced pump technology and DexCom’s SEVEN™ continuous glucose monitoring system. The new technology will enable the Animas® pump to receive glucose readings and display this information on the pump’s color screen. Users will have access to real-time glucose readings and trending in addition to receiving alerts for low and high glucose readings. Having real-time readings displayed on the pump screen will not only allow users to make more timely adjustments to their insulin delivery – it will eliminate a separate receiver, reducing the amount of equipment required to use CGM and the pump system.
MORE ON THIS TOPIC